US Patent Issued to BREATH THERAPEUTICS on Nov. 3 for "Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection" (German Inventors)

ALEXANDRIA, Va., Nov. 3 -- United States Patent no. 12,779,011, issued on Nov. 3, was assigned to BREATH THERAPEUTICS GMBH (Munich).

"Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection" was invented by Martin Knoch (Garmisch-Partenkirchen, Germany) and Oliver Denk (Munsing, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection. In particular, the invention provides a cyclosporine liquid formulation for use as an aerosol for inhalation in a method of preventing or treating pulmonary chronic graft rejection in single lung transplanted...